WCLC MEETING NEWS #WCLC21 OUR COMMITMENT TO ONCOLOGY TODAY’S CLINICAL RESEARCH DEVELOPS HOPE FOR TOMORROW VV-OTHR-US-DEL-0521 04/2021 © Lilly USA, LLC 2021. All rights reserved. ANNUAL MEETING EDUCATIONAL PROGRAM DESIGNED FOR EXCELLENCE, DIVERSITY, FLEXIBILITY A s part of its mission to provide critical thoracic cancer education to an international audience of multidisciplinary specialists, the IASLC remains committed to offering opportunities in the virtual space just like it has for decades of in-person conferences. World Conference on Lung Cancer (WCLC) 2021 Conference Chair David Harpole, MD, and Co- Chairs Kristin Higgins, MD, and Thomas A. Stinchcombe, MD, have led the programming efforts for WCLC 2021, to be held September 8-14 as a worldwide virtual event. They talked with WCLC News about what to expect at the upcoming meeting and the future of thoracic oncology. Answers were edited for length and clarity. What are some virtual features about the meeting that attendees will be excited about? Dr. Harpole: The WCLC is a very special annual meeting. Although there are several large regional oncology conferences each year, only the WCLC focuses on the global impact of thoracic malignancies. Moreover, despite the worldwide pandemic, research continued, and there have been many important advances in thoracic malignancies ... see WCLC on page 6 TETSUYA MITSUDOMI, MD, PHD, will conclude his 2-year tenure as IASLC president after the upcoming World Conference on Lung Cancer. Dr. Mitsudomi is a professor of thoracic surgery at Kindai University in Osaka, Japan. He also has served on the IASLC Board of Directors and as president of the Japanese Lung Cancer Society. Before this year’s meeting, Dr. Mitsudomi talked with WCLC Meeting News about the advancements and challenges that took place during his term. Answers have been edited for length and clarity. What accomplishments during your term give you the greatest satisfaction? My presidency was marked by change, challenges, and opportunities, most significantly the COVID-19 pandemic. The pandemic compelled the IASLC to rethink time-tested approaches and norms while forcing us to adapt, learn new skills, and adjust our behaviors. COVID-19 affected our work dramatically— from member engagement, to education and meetings, to communications, to scientific projects, to our finances and operations. Just as our members have risen to the challenge posed by this historic pandemic, whether through IASLC PRESIDENT SERVES DURING A TIME OF CHANGE, CHALLENGES, AND OPPORTUNITIES Tetsuya Mitsudomi, MD, PhD ... see PRESIDENT on page 14 CONQUERING THORACIC CANCERS WORLDWIDEPREVIEW EDITION INSIDE: PAGE 3 Connect at Brain Exchange sessions PAGE 4 JTO impact factor keeps increasing PAGE 7 WCLC’s worldwide schedule-at-a-glance PAGE 3 Post-diagnosis tobacco cessation PAGE 11 Interact with leaders at workshops WITH TETSUYA MITSUDOMI, MD, PhD Q & A Clockwise from top left: David Harpole, MD, Kristin Higgins, MD, and Thomas A.Stinchcombe, MD Q & A NOT REGISTERED YET? Visit wclc2021.iaslc.org and view the complete 2021 program and associated abstracts. The staggered program schedule allows for live attendance by members in every time zone. Registration information is available at wclc2021.iaslc.org/ registration.LOCATION STUDY TREATMENTS KEY ELIGIBILITY CRITERIA ASIA, AUSTRALIA, NORTH AMERICA RANDOMIZED, PHASE 2, OPEN-LABEL • Zimberelimab (anti-PD-1 antibody) • Domvanalimab(anti-TIGIT antibody)+ Zimberelimab • Domvanalimab + Zimberelimab + Etrumadenant (dual adenosine A 2a /A 2b receptor antagonist) NSCLC: • Histologically confirmed squamous or nonsquamous • PD-L1 positive • Metastatic • No EGFR or ALK mutations These molecules and their uses are investigational, have not been proven to be safe and effective, and have not been approved by any health authority. ASIA, EUROPE, LATIN AMERICA RANDOMIZED, PHASE 3, OPEN-LABEL • Zimberelimab • Chemotherapy • Domvanalimab + Zimberelimab NSCLC: • Histologically confirmed squamous or nonsquamous • Treatment-naive • PD-L1 positive • Locally advanced or metastatic • No EGFR or ALK mutations Do you have patients with NSCLC who could benefit from participating in an EXPLORE THE STUDIES AT arcusbio.com/clinical-trials/lung-cancer HAVE A PATIENT TO REFER? email us at clinicaltrials@arcusbio.com today! Arcus Biosciences, a company focused on precision combinations for cancer, is currently enrolling: ALK= anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer; PD-1=programmed death protein 1; PD-L1=programmed death ligand 1; TIGIT=T cell immunoreceptor with immunoglobulin and ITIM domain. © 2021 Arcus Biosciences, Inc. All rights reserved. Approved July 2021. ANTI-TIGIT CLINICAL TRIAL?PREVIEW EDITION | WORLDWIDE VIRTUAL EVENT3 TOBACCO MOMENTS PRESENTATIONS FOCUS ON POST-DIAGNOSIS CESSATION STRATEGIES I ASLC’s Tobacco Control and Smoking Cessation Committee will present four short presentations highlighting the importance and strategies for tobacco cessation following a diagnosis of lung or other thoracic malignancy. Tobacco Moments are 3 to 4-minute presentations providing tobacco control and smoking cessation knowledge to broad audiences of nontobacco experts. These presentations will be part of four Education Sessions during WCLC. Tobacco Moments debuted at the IASLC North America Conference on Lung Cancer 2020. Joelle Fathi, DNP, ARNP, CTTS, spearheaded the effort to include Tobacco Moments, created and sponsored by the Tobacco Control and Smoking Cessation Committee, at IASLC meetings. Dr. Fathi noted that those patients with early-stage lung cancer who quit smoking have nearly a 2-fold increase in 5-year survival rates than those patients who continue to smoke. Health care providers with the knowledge and skills to help their patients who use tobacco to stop tobacco usage help fulfill the IASLC’s mission “to use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.” “What we are often not thinking about is that if we help those patients who smoke to quit smoking, we can optimize their response to treatment, including surgery, chemotherapy, or targeted therapy. Helping our patients successfully quit smoking improves their chances for remission and lowers their chances of recurrent disease and development of a second primary tobacco-related cancer,” Dr. Fathi said. “Robust tobacco cessation services should be integrated into all of our treatment plans across the care continuum. We know that exposure to tobacco smoke causes lung cancer. The best way to prevent, cure, and save people from lung cancer is to aggressively treat tobacco dependence and cigarette smoking. Our patients need it and deserve it.” Matthew Steliga, MD, Chair of the IASLC’s Tobacco Control and Smoking Cessation Committee said that the committee believes that Tobacco Moments offer a great opportunity to provider pertinent information about improving lung cancer outcomes through discussions about how tobacco control impacts lung cancer treatment. “Most IASLC members are not tobacco experts, but we’re interfacing with tobacco use every day,” Dr. Steliga said. “Our goal is to give people basic tools and information about tobacco that can help them in their primary role, whether that’s as a medical oncologist, a radiation therapist, a radiation oncologist, nursing, surgery, or another role. Tobacco really is interdisciplinary across the specialty and a challenge that we all face together.” Joelle Fathi, DNP, ARNP, CTTS Matthew Steliga, MD TOBACCO MOMENTS AT WCLC 2021 FRIDAY, SEPT. 10 The criticality of development of a validated tobacco use measurement tool in clinical trials (captured, considered in clinical endpoints and final analysis) Carolyn Dresler Part of ES09: Pathology Assessment and Biomarker Testing: Implications of and for Adjuvant and Neoadjuvant Therapy — 10:30–11:05 MDT Tobacco Dependence Treatment Guideline Update (American Thoracic Society Tobacco Treatment Guidelines released in 2020) Frank Leone Part of ES10: Optimizing Clinical Outcomes in Lung Cancer: The Value of Tobacco Cessation — 11:15–11:50 MDT TUESDAY, SEPT. 14 The Intersection of Tobacco Use, Health Disparities, and Inequities in Lung Cancer, Treatment, and Survival Abhishek Shankar Part of ES13: Ethics, Costs, and Regulation of Lung Cancer — 17:30–18:05 MDT Critical Components of Successful Smoking Cessation Outcomes Magdalena Cedzynska Part of ES12: A Precision Approach to Stage III Non-small Cell Lung Cancer — 17:30–18:05 MDT BRAIN EXCHANGE SESSIONS OFFER A PLACE TO CONNECT WITH COLLEAGUES, SHARE IDEAS NEW IN 2021, BRAIN EXCHANGE discussions will create an intimate learning environment with a focus on networking. These sessions will allow attendees the opportunities to create new professional relationships, ask questions of experts, and learn more about specific topics or industry focuses. The first group of Brain Exchange sessions will be on Sept. 10 from 12:00–13:00 MDT, and the second group will be held on Sept. 13 from 21:15–22:15. Each Brain Exchange session will take place live and last for an hour. All sessions will be limited to 50 attendees and start with a short presentation from a facilitator or panelists, followed by an open conversation among all attendees. Speakers are encouraged to pose questions to attendees, and all attendee questions are expected to be answered during the course of the session. “The Brain Exchange sessions will be more informal, trying to simulate that environment that you would have at an in-person conference where people gather around the coffee stand and rehash some of the new data that they have seen, along with chat about other topics,” WCLC Co-Chair Kristin Higgins, MD, said. “This will be a good opportunity to have more intimate and informal discussions with your colleagues around the world.” Some sessions will be organized by the IASLC, while others will be sponsored by industry. Brain Exchange sessions are not CME accredited. Friday, Sept. 10, 12:00–13:00 MDT • Meet the Nurse and Allied Health Committee • Lung Ambition Alliance — Accelerating the Early Diagnosis of Lung Cancer at Local Level • Sip and Chat with the FDA • AstraZeneca (INDUSTRY) — ‘Defining Cure’ in Stage III Unresectable NSCLC Management to long term survivors • Oncocyte (INDUSTRY) — Management of Early-Stage NSCLC Monday, Sept. 13, 21:15–22:15 MDT • IASLC Language Guide Idea Exchange on Adoption and Best Practices • Lung Ambition Alliance — Accelerating the Early Diagnosis of Lung Cancer at a Local Level Check wclc2021.iaslc.org for the most up-to- date schedule of topics and speakers and to sign up for the sessions. 4IASLC WORLD CONFERENCE ON LUNG CANCER | #WCLC21 JOURNAL OF THORACIC ONCOLOGY IMPACT FACTOR CONTINUES TO INCREASE THE IASLC REPORTS THAT ITS MAIN CANCER journal, the Journal of Thoracic Oncology (JTO), improved its Impact Factor from 13.357 in 2019 to 15.609 in 2020. The JTO, the official journal of the IASLC, now ranks 13th out of all 242 oncology journals and 4th out of the 64 respiratory system journals. “It is generally difficult for organ-specific oncology journals to make a significant impact in the oncology publishing landscape. With an Impact Factor of 15.609, JTO is the leading journal in thoracic oncology and in the top fifteen of all cancer journals,” said Editor- in-Chief Alex A. Adjei, MD. “JTO’s emphasis on multidisciplinary research is one of its strengths and serves the broad community of researchers in this field.” Impact Factors are measured by calculating the number of times journal articles in the two preceding years are cited in a current year. Thus, the Impact Factor for 2020 is the number of times articles published in 2018 and 2019 are cited in 2020. The higher the Impact Factor, the more highly ranked the journal. Journal citation reports are issued by Clarivate Analytics. The JTO is the primary educational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Emphasizing a multidisciplinary approach, the JTO includes original research, review articles and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists and basic scientists with a special interest in thoracic oncology. OPEN-ACCESS COMPANION The JTO Clinical and Research Reports (JTO CRR), IASLC’s open-access companion title, also features novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. The JTO CRR publishes a range of manuscripts from subset analyses of published trials to high-quality case reports and has had several of its own important milestones this year. The JTO CRR successfully transitioned first from a quarterly to a monthly publication in January 2021 and then to article- based publishing later that same month. This publishing model allows an individual article to be citable in its final format upon receipt of the author’s finalized corrections, providing final citations more quickly for authors and colleagues to share on their professional and personal social networks. The IASLC journals staff is hopeful that the JTO CRR will soon be indexed by PubMed and Scopus, having filed the application in April 2021. Visit the IASLC Journals Booth in the Exhibit Hall during the WCLC to learn more about each journal, including how to become a reviewer. The full contents of the JTO are a free benefit for IASLC members. Alex A. Adjei, MD, Editor-in-Chief ILCF FUNDS WORK OF YOUNG RESEARCHERS T he International Lung Cancer Foundation (ILCF) works to accelerate the pace of thoracic malignancy research, to inspire researchers to focus their careers on lung cancer, and to reduce the worldwide lung cancer mortality rate. 100% of every dollar donated goes directly to fund lung cancer research. The ILCF is pleased to present two individuals with the 2021 ILCF Young Investigator Award through the ILCF Research Awards Program. The ILCF Research Awards Program is a global education initiative funding Young Investigator Awards and Fellowships for training of research scientists pursuing careers in lung cancer diagnosis, treatment, or laboratory research, as well as other aspects of the study of lung tumors. ICLF Research Grants have given a boost to scores of research careers. Since its inception in 2012, the ILCF has awarded more than $6 million to 136 individuals, and many of the past recipients will present during WCLC 2021. Visit the Awards Lounge during the WCLC to learn more about these award recipients. Also, watch for special donation challenges during WCLC and visit www.iaslc.org/international-lung-cancer- foundation to donate or learn more. During WCLC, the ILCF will make it easier than ever to show your financial support with a new text-to-donate feature and ways to get involved through the meeting platform, which will feature a live donor wall saluting those who support the IASLC and the Foundation. Chiara Ambrogio, PhD University of Turin, Italy Project: “Identification of On-target and Off Target Resistance to KRAS-G12C Inhibitors by Comparing KRAS Inhibition Versus KRAS Degradation” Andrew Chow, MD, PhD Memorial Sloan Kettering Cancer Center, United States Project: “Leveraging CD39 as a Biomarker of Tumor-Reactive CD8+ T cells to Improve Precision Immunotherapy” Afaf Abed, MBBS Edith Cowan University, Australia Project: “Genomic HLA and pre-treatment TCR repertoire as biomarkers of response to immunotherapy in advanced non-small cell lung cancer patients” Adithya Balasubramanian, MBBS, BMedSci Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Australia Project: “Deciphering the regulation of the antigen presentation machinery in lung adenocarcinoma and its impact on response to immunotherapy” Jose Carlos Benitez, MD, PhD Institut Gustave Roussy, France Project: “Immune and molecular characterization of Thymic Epithelial Tumors enrolled in IFCT-1104 RYTHMIC” Misty Shields, MD, PhD University of South Florida, Moffitt Cancer Center, United States Project: “Investigation of APR-246 in small cell lung cancer” 2021 ILCF FELLOWSHIP GRANT WINNERS 2021 ILCF YOUNG INVESTIGATOR AWARD WINNERSWHAT’S YOUR PLAN TO TEST FOR RET ? Consider NGS to find actionable biomarkers, includingRET, in NSCLC and thyroid cancers INCLUDE RET FUSIONS AND RET POINT MUTATIONS IN YOUR BIOMARKER TESTING PROTOCOL FOR APPROPRIATE PATIENTS NGS=next-generation sequencing; NSCLC=non-small cell lung cancer; RET=rearranged during transfection. PP-SE-US-0739 06/2021 © Lilly USA, LLC 2021. All rights reserved.6IASLC WORLD CONFERENCE ON LUNG CANCER | #WCLC21 WCLC, CONTINUED FROM THE COVER … that are worthy of an international forum to disseminate these significant findings. WCLC 2021 will highlight many of these data. Dr. Stinchcombe: It has been a big adjustment converting to the virtual meetings during the past 12 to 18 months with the COVID pandemic. With each event, the IASLC has made some adjustment to the virtual features. We have scheduled the WCLC so it is staggered over several days and available at good times in multiple time zones. The virtual environment allows greater flexibility—so if you are in clinic all day, you can view the meeting after clinic. Virtual meetings also expand access to a greater number of attendees. Dr. Higgins: On Saturday, September 11, we set up regional workshops for different parts of the world so that those groups can talk about content that is perhaps distinct to their region. These workshops are an attempt to simulate the ability for people to gather as distinct, intentional groups to talk about the common themes that are important to different regions of the world, similar to how we debrief in hallways at live events with our colleagues. We also have the Young Investigators workshop and the Women in Thoracic Oncology workshop that day. What themes, sessions or presentations are you looking forward to the most, and why? Dr. Harpole: Prior to constructing the meeting format, we solicited input from various IASLC stakeholders to define the strengths and weaknesses of previous WCLCs. In addition, the virtual format added flexibility to the types of forums that were possible. An initial step toward a novel meeting format was the selection of a Program Committee that more accurately reflected IASLC’s global membership. These individuals have created a meeting with a list of invited speakers for our educational sessions and abstract discussions, having a strong focus on participation from IASLC members from geographically, culturally, and gender-diverse backgrounds, as well as diverse in their medical specialties. This diversity will allow cross-pollination of many different perspectives. Dr. Stinchcombe: For many of the educational sessions, we have made sure that they are multidisciplinary with good representation from all the specialties—medical oncology, radiation oncology, thoracic surgery, and cancer biology, in addition to others. We have also divided the tracks to represent specific types of therapy such as targeted therapies and immunotherapy, for example. We are hopeful that the new data are presented in a user-friendly format that allows each attendee to easily find topics of interest. Historically, the virtual format has been more challenging for poster presenters. This year, we have tried to make sure that the posters are included in the meeting in meaningful ways. Dr. Higgins: We have designed our plenary sessions to really focus on key aspects of thoracic oncology. One of the plenaries is focused on disparities in thoracic oncology, which is such an important topic across the world. We have some great thought leaders that are going to be giving presentations that should inspire us about ways that we can take action and reach patients whom we have not been able to reach before with therapies. Looking into both the short- and long-term future, what are your hopes for the thoracic oncology community? Dr. Harpole: Having been an investigator in thoracic malignancies for nearly 3 decades, I am most excited about the accelerated pace of the significant innovation in lung cancer care during the past 5 years. Making lung cancer a chronic disease seemed an impossible dream a few years ago, but is getting ever closer to a reality. Pessimism has been replaced with optimism and dreams have come true, as we have become “the cool kids” of oncology. Dr. Stinchcombe: The number of targeted therapies approved for patients with specific genomic alterations is always increasing. Immunotherapy has revolutionized the care of patients with lung cancer. We have also made improvements in supportive care and integrated palliative care into routine clinical care. We have a more comprehensive care team than 10 or 15 years ago, and patients are living longer with a better quality of life. Dr. Higgins: We have seen an incredible pace of scientific discovery with the way that the COVID vaccines were developed, for example, and taking that ability to move new therapies forward at such a rapid rate is something that we can apply further to our cancer treatments. It is inspirational, and everything that the world has gone through with the COVID pandemic, I think, continues to inspire us as oncologists to do better for our patients in ways that we have seen done across the world. What are some of the promising areas and some of the challenges you see ahead for your specialty and the thoracic oncology community as a whole? Dr. Harpole: As a thoracic surgeon, the IASLC, and specifically the WCLC, have been instrumental in disseminating the advantages of minimally invasive techniques for optimal local control of thoracic malignancies that have not only made care safer, but also have increased the pool of patients who may have successful resection. In addition, CT screening is identifying lesions at an earlier stage. Future research that integrates biomarkers including minimal residual disease, innovative neoadjuvant strategies, and improved instrumentation for localizing/treating solitary nodules will continue to push the survival curves higher. Dr. Stinchcombe: One of the major challenges that we face with the proliferation of therapies and interventions is making sure that all patients have access to them. We have recognized that within the United States there are disparities in access to medical care and recent advances. Globally we have become increasingly aware over the past several years that we need to make sure that care and advances can be implemented in low- and middle-income countries. Participation in screening programs is below what most of us have hoped for given the benefit. That is another area that needs to be a focus since, obviously, detecting patients with early-stage disease carries a better prognosis and a higher cure potential. Dr. Higgins: Immunotherapy has been such a game-changer for lung cancer, and now we are seeing it integrated into the surgical management of the disease. Moving immunotherapy into earlier stages of disease is really exciting, and having the opportunity to actually cure more patients is thrilling for us as oncologists. We also need to identify patients with earlier stages of diseases, which is why screening remains something that is very, very important. David Harpole, MD An initial step toward a novel meeting format was the selection of an organizing committee that more accurately reflected IASLC’s global membership. These individuals have created a meeting with a list of invited speakers for our educational sessions and our discussions, having a strong focus on participation from IASLC members from geographically, culturally, and gender-diverse backgrounds, as well as diverse in their medical specialties.”PREVIEW EDITION | WORLDWIDE VIRTUAL EVENT7 Meet the Expert Session San Francisco: 4:45–5:45 PDT Denver: 5:45–6:45 MDT New York: 7:45–8:45 EDT Rome: 14:15–17:45 UCT Singapore: 19:45–20:45 SGD Sydney: 21:45–22:45 AEST Plenary Session San Francisco: 6:00–7:00 PDT Denver: 7:00–8:00 MDT New York: 9:00–10:00 EDT Rome: 13:00–14:00 UCT Singapore: 21:00–22:00 SGD Sydney: 23:00–0:00* AEST Oral Abstract/Mini Oral Abstract Sessions San Francisco: 7:15–10:45 PDT Denver: 8:15–11:45 MDT New York: 10:15–13:45 EDT Rome: 14:15–17:45 UCT Singapore: 22:15–1:45* SGD Sydney: 0:15*–3:45* AEST Opposed Industry or Satellite CME Symposia San Francisco: 11:00–12:00 PDT Denver: 12:00–13:00 MDT New York: 14:00–15:00 EDT Rome: 18:00–19:00 UCT Singapore: 2:00*–3:00* SGD Sydney: 4:00*–5:00* AEST Unopposed Industry or Satellite CME Symposia San Francisco: 4:15–5:15 PDT Denver: 5:15–6:15 MDT New York: 7:15–8:15 EDT Rome: 11:15–12:15 UCT Singapore: 19:15–20:15 SGD Sydney: 21:15–22:15 AEST Meet the Expert Session San Francisco: 4:15–5:15 PDT Denver: 5:15–6:15 MDT New York: 7:15–8:15 EDT Rome: 11:15–12:15 UCT Singapore: 19:15–20:15 SGD Sydney: 21:15–22:15 AEST Presidential Symposium San Francisco: 5:30–7:00 PDT Denver: 6:30–8:00 MDT New York: 8:30–10:00 EDT Rome: 12:30–14:00 UCT Singapore: 20:30–22:00 SGD Sydney: 22:30–0:00* AEST Oral Abstract/Mini Oral Abstract Sessions San Francisco: 7:15–12:00 PDT Denver: 8:15–13:00 MDT New York: 10:15–15:00 EDT Rome: 14:15–19:00 UCT Singapore: 22:15–3:00* SGD Sydney: 0:15*–5:00* AEST Opposed Industry or Satellite CME Symposia San Francisco: 12:15–13:15 PDT Denver: 13:15–14:15 MDT New York: 15:15–16:15 EDT Rome: 19:15–20:15 UCT Singapore: 3:15*–4:15* SGD Sydney: 5:15*–6-15* AEST Presidential Symposium (Re-Broadcast) San Francisco: 13:30–15:00 PDT Denver: 14:30–16:00 MDT New York: 16:30–18:00 EDT Rome: 20:30–22:00 UCT Singapore: 4:30*–6:00* SGD Sydney: 6:30*–8:00* AEST Opposed Industry or Satellite CME Symposia San Francisco: 4:45–5:45 PDT Denver: 5:45–6:45 MDT New York: 7:45–8:45 EDT Rome: 11:45–12:45 UCT Singapore: 19:45–20:45 SGD Sydney: 21:45–22:45 AEST Educational Sessions San Francisco: 6:00–10:50 PDT Denver: 7:00–11:50 MDT New York: 9:00–13:50 EDT Rome: 13:00–17:50 UCT Singapore: 21:00–1:50* SGD Sydney: 23:00–3:50* AEST Brain Exchange Discussion Groups San Francisco: 11:00–12:00 PDT Denver: 12:00–13:00 MDT New York: 14:00–15:00 EDT Rome: 18:00–19:00 UCT Singapore: 2:00*–3:00* SGD Sydney: 4:00*–5:00* AEST Regional Workshops Check the online planner for details Meet the Expert Session San Francisco: 14:00–15:00 PDT Denver: 15:00–16:00 MDT New York: 17:00–18:00 EDT Rome: 21:00–22:00 UCT Singapore: 5:00*–6:00* SGD Sydney: 7:00*–8:00* AEST IASLC General Assembly San Francisco: 14:30–15:00 PDT Denver: 15:30–16:00 MDT New York: 17:30–18:00 EDT Rome: 21:30–22:00 UCT Singapore: 5:30*–6:00* SGD Sydney: 7:30*–8:00* AEST Plenary Session San Francisco: 15:15–16:15 PDT Denver: 16:15–17:15 MDT New York: 18:15–19:15 EDT Rome: 22:15–23:15 UCT Singapore: 6:15*–7:15* SGD Sydney: 8:15*–9:15* AEST Oral Abstract/Mini Oral Abstract Sessions San Francisco: 16:30–20:00 PDT Denver: 17:30–21:00 MDT New York: 18:30–23:00 EDT Rome: 23:30–3:00* UCT Singapore: 7:30*–11:00* SGD Sydney: 9:30*–13:00* AEST Opposed Industry or Satellite CME Symposia San Francisco: 20:15–21:15 PDT Denver: 21:15–22:15 MDT New York: 23:15–0:15* EDT Rome: 3:15*–4:15* UCT Singapore: 11:15*–12:15* SGD Sydney: 13:15*–14:15* AEST Unopposed Industry or Satellite CME Symposia San Francisco: 15:15–16:15 PDT Denver: 16:15–17:15 MDT New York: 18:15–19:15 EDT Rome: 22:15–23:15 UCT Singapore: 6:15*–7:15*SGD Sydney: 8:15–9:15* AEST Oral Abstract/Mini Oral Abstract Sessions San Francisco: 16:30–20:00 PDT Denver: 17:30–21:00 MDT New York: 19:30–23:00 EDT Rome: 23:30–3:00* UCT Singapore: 7:30*–11:00* SGD Sydney: 9:30*–13:00* AEST Brain Exchange Discussion Groups San Francisco: 20:15–21:15 PDT Denver: 21:15–22:15 MDT New York: 23:15*–0:15* EDT Rome: 3:15*–4:15* UCT Singapore: 11:15*–12:15* SGD Sydney: 13:15*–14-15* AEST Opposed Industry or Satellite CME Symposia San Francisco: 14:00–15:00 PDT Denver: 15:00–16:00 MDT New York: 17:00–18:00 EDT Rome: 21:00–22:00 UCT Singapore: 5:00*–6:00* SGD Sydney: 7:00*–8:00* AEST Meet the Expert Session San Francisco: 14:00–15:00 PDT Denver: 15:00–16:00 MDT New York: 17:00–18:00 EDT Rome: 21:00–22:00 UCT Singapore: 5:00*–6:00* SGD Sydney: 7:00*–8:00* AEST Plenary Session San Francisco: 15:15–16:15 PDT Denver: 16:15–17:15 MDT New York: 18:15–19:15 EDT Rome: 22:15–23:15 UCT Singapore: 6:15*–7:15* SGD Sydney: 8:15*–9:15* AEST Educational Sessions San Francisco: 16:30–20:05 PDT Denver: 17:30–21:05 MDT New York: 19:30–23:05 EDT Rome: 23:30–3:05* UCT Singapore: 7:30*–11:05* SGD Sydney: 9:30–13:05* AEST Plenary Session San Francisco: 20:15–21:15 PDT Denver: 21:15–22:15 MDT New York: 23:15–0:15* EDT Rome: 3:15*–4:15* UCT Singapore: 11:15*–12:15* SGD Sydney: 13:15*–14:15* AEST PROGRAMMING TIMED FOR A WORLDWIDE AUDIENCE DAY 1: WEDNESDAY, SEPTEMBER 8 DAY 2: THURSDAY, SEPTEMBER 9 DAY 3: FRIDAY, SEPTEMBER 10 DAY 4: SATURDAY, SEPTEMBER 11 DAY 5: SUNDAY, SEPTEMBER 12 DAY 6: MONDAY, SEPTEMBER 13 DAY 7: TUESDAY, SEPTEMBER 14 TO HELP MAXIMIZE YOUR WCLC 2021 experience, full-length educational sessions will be released on September 1. Watch the full education sessions first, then participate in live-streamed discussions on September 10 and 14. Content will be available to registered attendees for an extended period after the meeting, as well. View the program at wclc2021.iaslc.org/program-at-a-glance/ . *Indicates next dayReference: COSELA (trilaciclib). Prescribing Information. G1 Therapeutics, Inc; 02/2021. G1 Therapeutics™ and the G1 Therapeutics logo, COSELA™ and the COSELA logo are trademarks of G1 Therapeutics, Inc. ©2021 G1 Therapeutics, Inc. All rights reserved. US-2100258 07/2021 SPARE THE MARROW. COSELA HELPS PROTECT AGAINST MYELOSUPPRESSION, PROACTIVELY HELP PROTECT AGAINST MULTIPLE MYELOSUPPRESSIVE CONSEQUENCES WITH THE FIRST AND ONLY MYELOPROTECTION THERAPY The Pivotal Study (Study 1) compared an etoposide/carboplatin + atezolizumab (E/P/A) regimen with COSELA vs without COSELA* To decrease the incidence of chemotherapy-induced myelosuppressionin patients when administered prior to a platinum/ etoposide-containing regimen or topotecan-containing regimen FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) COSELA™ (trilaciclib) helps protect hematopoietic stem and progenitor cells (HSPCs), the source of blood cell lineages INDICATION COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). * COSELA was evaluated in 3 randomized, double-blind, placebo-controlled clinical studies. The Pivotal Study (Study 1) evaluated COSELA or placebo administered prior to treatment with E/P/A in 107 patients with newly diagnosed ES-SCLC not previously treated with chemotherapy. In this study, COSELA significantly reduced the primary endpoints of incidence (adjusted relative risk [aRR] 0.038 [95% CI, 0.008, 0.195], P<0.0001) and duration in Cycle 1 (mean difference -3.6 [95% CI, -4.9, -2.3], P<0.0001) of severe neutropenia and significantly decreased the rate of all-cause chemotherapy dose reductions (aRR 0.242 [95% CI, 0.079, 0.742]). The incidence of Grade 3/4 anemia was 19% and 28% (aRR 0.663 [95% CI, 0.336, 1.310]) and RBC transfusions on/after 5 weeks were 13% and 21% (aRR 0.642 [95% CI, 0.294, 1.404]) with and without COSELA, respectively. VISIT COSELA.COM FOR MORE DETAILSTo report suspected adverse reactions, contact G1 Therapeutics at 1-800-790-G1TX or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. This information is not comprehensive. Please see the Brief Summary of Prescribing Information on the adjacent page. SPEAR THE TUMOR. WHILE CHEMOTHERAPY TARGETS CANCER CELLS SELECT IMPORTANT SAFETY INFORMATION CONTRAINDICATION • COSELA is contraindicated in patients with a history of serious hypersensitivity reactions to trilaciclib. WARNINGS AND PRECAUTIONS Injection-Site Reactions, Including Phlebitis and Thrombophlebitis • COSELA administration can cause injection-site reactions, including phlebitis and thrombophlebitis, which occurred in 56 (21%) of 272 patients receiving COSELA in clinical trials, including Grade 2 (10%) and Grade 3 (0.4%) adverse reactions. Monitor patients for signs and symptoms of injection-site reactions, including infusion-site pain and erythema during infusion. For mild (Grade 1) to moderate (Grade 2) injection-site reactions, flush line/cannula with at least 20 mL of sterile 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP after end of infusion. For severe (Grade 3) or life-threatening (Grade 4) injection-site reactions, stop infusion and permanently discontinue COSELA. Injection-site reactions led to discontinuation of treatment in 3 (1%) of the 272 patients. Acute Drug Hypersensitivity Reactions • COSELA administration can cause acute drug hypersensitivity reactions, which occurred in 16 (6%) of 272 patients receiving COSELA in clinical trials, including Grade 2 reactions (2%). Monitor patients for signs and symptoms of acute drug hypersensitivity reactions. For moderate (Grade 2) acute drug hypersensitivity reactions, stop infusion and hold COSELA until the adverse reaction recovers to Grade ≤1. For severe (Grade 3) or life-threatening (Grade 4) acute drug hypersensitivity reactions, stop infusion and permanently discontinue COSELA. Interstitial Lung Disease/Pneumonitis • Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with cyclin- dependent kinases (CDK)4/6 inhibitors, including COSELA, with which it occurred in 1 (0.4%) of 272 patients receiving COSELA in clinical trials. Monitor patients for pulmonary symptoms of ILD/pneumonitis. For recurrent moderate (Grade 2) ILD/ pneumonitis, and severe (Grade 3) or life-threatening (Grade 4) ILD/pneumonitis, permanently discontinue COSELA. Embryo-Fetal Toxicity • Based on its mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use an effective method of contraception during treatment with COSELA and for at least 3 weeks after the final dose. ADVERSE REACTIONS • The most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia. Only approved for use in the US.Next >